Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Clinical trials
649 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (104)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06119269 | Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase(PHOENICS) | recruiting | — | 100 | University of PisaOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06390306 | The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP | recruiting | — | 30 | Peking University People's HospitalOTHER | 1 | Jun 3, 2025 |
| clinicaltrials |
| NCT06757855 | Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML | recruiting | Phase 1 / Phase 2 | 29 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06355583 | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial(MAST) | recruiting | Phase 2 | 50 | Imperial College LondonOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT05130138 | Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia(PHARM-LMC) | recruiting | N/A | 100 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT05282108 | Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia(CARCML) | recruiting | — | 240 | Hikma Pharmaceuticals LLCINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06453902 | TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients | recruiting | Phase 2 | 40 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05682924 | Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib | recruiting | — | 105 | Samara State Medical UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06532084 | Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen(SoraGVL) | recruiting | Phase 2 | 88 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06508099 | Vitamin A and D Supplementation in Allogeneic HCT(VitaStem) | recruiting | Phase 2 | 220 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05439889 | Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission | recruiting | — | 100 | National Taiwan University HospitalOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05963061 | Chronic Myeloid Leukemia (CML) Real-Life Database | recruiting | — | 3,500 | University Hospital, Clermont-FerrandOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06211166 | Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction | recruiting | — | 300 | Peking University People's HospitalOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT01281735 | International Chronic Myeloid Leukemia Pediatric Study(ICMLPed) | recruiting | — | 750 | Poitiers University HospitalOTHER | 20 | Jan 17, 2024 | clinicaltrials |
| NCT05367700 | A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. | recruiting | Phase 1 | 108 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 13, 2023 | clinicaltrials |
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04769947 | Italian Treatment Free Remission Registry | recruiting | — | 800 | University of Turin, ItalyOTHER | 1 | Nov 18, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 5, 2025source: clinicaltrials